Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By Freedom Bunker
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Netflix Preview: “A Crowded Long And Defensive Save Haven For Tech Investors”

% of readers think this story is Fact. Add your two cents.


Netflix Preview: “A Crowded Long And Defensive Save Haven For Tech Investors”

NFLX reports earnings right after the close (~4:02pm ET) with conference call at 4:45pm ET. 

With 1Q marking the first quarter of no subscriber / net adds disclosures, the tactical ‘subs’ debate has quieted down (yes, still some q/q questions off the big 4Q and/or how to think about the WSJ story earlier in the week about the company hitting a $1 trillion market cap, which seemed like a planted attempt to smoke out shorts ahead of earnings and give the stock a buffer to fall from on disappointing news) with most of the debate around who will be the ‘incremental buyer’ of Netflix shares post print as the valuation us starting to stick out relative to large-cap Internet peers (albeit vs expectations for Netflix to deliver what may be a rare ‘beat’ on earnings given perceived insulation from a number of the ‘headwinds’ out there – e.g. macro slowdown, tariffs, AI capex, etc).

Here are Wall Street consensus estimates

  • Q1 EPS $5.763
  • Q1 Revenue $10.496BN
  • Q1 Operating Profit: $3.00BN
  • Q1 Net Income $2.484BN

… and UBS’ bogeys:

  • Q1 Revenue Growth Reported: $10.5bn/up 12% y/y
  • Q1 Revenue Growth FXN: $15%
  • Q1 EBIT: $3 bn
  • Q2 Revenue Growth FXN: up 16%
  • Q2 EBIT: around $3.3 bn
  • FY25 Operating Margin: reiterate versus prior guide 29% (some hopes for a slight walk up)
  • FY25 Revenue Guide: reiterate versus prior guide $43.5-44.5 bn/14-17% y/y

And visually

In its preview of NFLX earnings, UBS writes that “shockingly” the amount of inbound on bogeys has only picked up over the course of this past week. Netflix is a crowded long and has been a defensive safe haven with investors. 

According to UBS, the bar seems low, and they are the first one out of the gate, which has proved to be a lucrative move for them in the past.

Despite the broader market carnage, Netflix still comes up as a top name to own into 2025, so price action may be dictated more so by what management says to update (though not expected) FY25 and margin expansion (bulls playing for upside to the 100bp of growth, though it doesn’t feel like investors are playing for them to update this quarter). Netflix is also seen as a secular winner, with pricing power and solid underlying sub momentum given the competitive backdrop.

Investors will be focused on: 

  1. tone and confidence in ability to sustain double-digit revenue growth and margin expansion in 2025; 
  2. impact of recent pricing changes; 
  3. impacts to ad business given softer macro versus guide for double ad revs in 2025; 
  4. any implications for transitioning onto in-house ad platform along with any early learnings thus far; 
  5. updates on live content/sports strategy and gaming; 
  6. updates on content spend ($18 bn content spend versus $17 bn in 2024); and 
  7. competitive dynamics and what the pullback at peers is doing to their business.

Here, Goldman’s sellside desk chimes in and writes that in terms of idiosyncratic company debates coming out of the last earnings report, the bank expects investor debates to remain centered around: 

  1. the perceptions of competitive moat (both against traditional media competition and increasingly forward competition from YouTube, TikTok & Meta); 
  2. the ability for the company to continue to efficiently close the monetization gap when compared to consumption patterns; 
  3. how the ad supported tier might continue to scale; & 
  4. the rising focus on live entertainment in terms of the company’s content investments.

In its latest model, Goldman updated its forward estimates as follows: 

  1. slightly lowered forward net add trajectory by ~0.5mm on an annual basis (with a skew toward more ad supported subscriber adds in the coming quarters in terms of mix); 
  2. modestly lowered advertising revenue assumptions throughout the remaining quarters of 2025 reflecting a weakening (& less certain) advertising environment (especially among the type of brand advertising dollars that are deployed into NFLX’s platform). 

Goldman remains Neutral (on the shares on the back of a balanced risk/reward from current levels) and lowered its 12-month price target from $960 to $955.

Tyler Durden Thu, 04/17/2025 – 15:44


Source: https://freedombunker.com/2025/04/17/netflix-preview-a-crowded-long-and-defensive-save-haven-for-tech-investors/


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.


LION'S MANE PRODUCT


Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules


Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.



Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.


Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

MOST RECENT
Load more ...

SignUp

Login

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.